ENTX · Insider Trading
Entera Bio Ltd. Ordinary Shares
Every open-market purchase and sale reported by ENTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-07 | Haya Taitel | Director | A | +20,790 | — |
| 2026-08-07 | Miranda Jayne Toledano | Chief Executive Officer | A | +700,000 deriv. | — |
| 2026-08-07 | Gregory Burshtein | Chief of R&D | A | +180,000 deriv. | — |
| 2026-08-07 | Steven D Rubin | Director | A | +19,117 | — |
| 2026-08-07 | Sean Ellis | Director | A | +20,034 | — |
| 2026-08-07 | Geno J Germano | Director | A | +25,014 | — |
| 2026-08-07 | Yonatan Malca | Director | A | +22,815 | — |
| 2026-08-07 | Dana Yaacov-Garbeli | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-08-07 | Hillel Galitzer | Chief Operating Officer | A | +200,000 deriv. | — |
| 2026-08-07 | Miranda Jayne Toledano | Chief Executive Officer | A | +700,000 deriv. | — |
| 2026-08-07 | Steven D Rubin | Director | A | +19,117 | — |
| 2026-08-07 | Haya Taitel | Director | A | +20,790 | — |
| 2026-08-07 | Hillel Galitzer | Chief Operating Officer | A | +200,000 deriv. | — |
| 2026-08-07 | Yonatan Malca | Director | A | +22,815 | — |
| 2026-08-07 | Dana Yaacov-Garbeli | Chief Financial Officer | A | +140,000 deriv. | — |
| 2026-08-07 | Geno J Germano | Director | A | +25,014 | — |
| 2026-08-07 | Sean Ellis | Director | A | +20,034 | — |
| 2026-08-07 | Gregory Burshtein | Chief of R&D | A | +180,000 deriv. | — |
| 2026-07-16 | Miranda Jayne Toledano | Chief Executive Officer | A | +420,560 | — |
| 2026-05-08 | Dana Yaacov-Garbeli | Chief Financial Officer | A | +58,394 | — |
| 2026-05-08 | Gregory Burshtein | Chief of R&D | A | +87,591 | — |
| 2026-05-08 | Hillel Galitzer | Chief Operating Officer | A | +72,993 | — |
| 2026-03-11 | Geno J Germano | Director | Buy | +20,000 | +$26.00K |
| 2026-03-09 | Sean Ellis | Director | Buy | +10,000 | +$12.30K |
| 2026-02-17 | Steven D Rubin | Director | Buy | +5,000 | +$7.45K |
| 2026-02-11 | Geno J Germano | Director | Buy | +20,000 | +$29.80K |
| 2026-02-11 | Sean Ellis | Director | Buy | +18,000 | +$22.32K |
| 2026-02-11 | Haya Taitel | Director | Buy | +7,500 | +$11.10K |
| 2026-02-11 | Steven D Rubin | Director | Buy | +10,000 | +$12.00K |
| 2026-01-02 | Sean Ellis | Director | A | +25,371 | — |
| 2026-01-02 | Gerald M Ostrov | Director | A | +28,721 | — |
| 2026-01-02 | Haya Taitel | Director | A | +26,329 | — |
| 2026-01-02 | Yonatan Malca | Director | A | +30,157 | — |
| 2026-01-02 | Gerald M Lieberman | Director | A | +38,294 | — |
| 2025-12-30 | Miranda Jayne Toledano | Chief Executive Officer | Buy | +11,000 | +$19.91K |
| 2025-07-18 | Dana Yaacov-Garbeli | Chief Financial Officer | A | +26,316 | — |
| 2025-07-18 | Gregory Burshtein | Chief of R&D | A | +26,316 | — |
| 2025-07-18 | Miranda Jayne Toledano | Chief Executive Officer | A | +180,702 | — |
| 2025-04-30 | Hillel Galitzer | Chief Operating Officer | A | +26,316 | — |
| 2025-04-03 | Gerald M Lieberman | Director | M | +23,952 | +$23.95K |
| 2025-01-17 | Sean Ellis | Director | A | +7,100 | — |
| 2025-01-17 | Yonatan Malca | Director | A | +8,216 | — |
| 2025-01-17 | Haya Taitel | Director | A | +6,922 | — |
| 2025-01-17 | Gerald M Ostrov | Director | A | +8,038 | — |
| 2025-01-17 | Gerald M Lieberman | Director | A | +10,717 | — |
| 2024-10-04 | Haya Taitel | Director | A | +7,278 | — |
| 2024-10-04 | Gerald M Ostrov | Director | A | +8,452 | — |
| 2024-10-04 | Sean Ellis | Director | A | +7,466 | — |
| 2024-10-04 | Yonatan Malca | Director | A | +8,639 | — |
| 2024-10-04 | Gerald M Lieberman | Director | A | +11,269 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Miranda Jayne Toledano | Chief Executive Officer | 774,142 | $2.21M |
| Gerald M Lieberman | Director | 344,654 | $985.71K |
| Dana Yaacov-Garbeli | Chief Financial Officer | 258,172 | $738.37K |
| Sean Ellis | Director | 208,132 | $595.26K |
| Gregory Burshtein | Chief of R&D | 189,033 | $540.63K |
| Hillel Galitzer | Chief Operating Officer | 163,566 | $467.80K |
| Haya Taitel | Director | 119,269 | $341.11K |
| Yonatan Malca | Director | 100,231 | $286.66K |
| Gerald M Ostrov | Director | 75,657 | $216.38K |
| Geno J Germano | Director | 65,014 | $185.94K |
| Steven D Rubin | Director | 34,117 | $97.57K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.